CD75/CD75s Mouse anti-Human, Alexa Fluor 647, Clone: ZB55, BD
Mouse Monoclonal Antibody
Manufacturer: BD Biosciences 566350
The ZB55 monoclonal antibody specifically recognizes the carbohydrate CD75 (lactosamines) and CD75s (sialylated lactosamines) antigens which are expressed in association with various glycolipids and glycoproteins. CD75 is expressed on mature B cells and germinal center B lymphocytes whereas CD75s is expressed on mature B cells. CD75 expression is lost on B cells differentiating to plasma cells whereas CD75s expression is lost on both germinal center B cells and B cells differentiating into plasma cells. CD75 and CD75s may be expressed by some T cells and can be useful markers for distinguishing different types of malignant B cells.Alexa Fluor™ 647 conjugates are highly photostable and remain fluorescent over a broad pH range. The excitation and emission maxima are nearly identical to those of APC. However, APC tends to be brighter while Alexa Fluor™ 647 is more optimal for intracellular applications. This fluorochrome exhibits uncommon photostability, making it an ideal choice for use in fluorescence microscopy. Due to nearly identical excitation and emission properties but different spillover characteristics, APC and Alexa Fluor™ 647 cannot be used simultaneously.
|Alexa Fluor 647|
|Mouse IgM, κ|
|Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.|
|Aqueous buffered solution containing BSA, protein stabilizer, and ≤0.09% sodium azide.|
|Human CD32 Peptides|
|The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to Alexa Fluor™ 647 under optimum conditions, and unreacted Alexa Fluor™ 647 was removed.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok